Generate Biomedicines(NASDAQ) GENB

Generate Biomedicines, Inc. uses artificial intelligence to create new protein medicines. These treatments help people fighting severe asthma and complex cancers. The technology builds new medicines that traditional methods cannot reach.

Designing New Medicines

• The Generate Platform: Machine learning system that designs and tests new protein treatments for various diseases.
• GB-0895 Candidate: Long-acting antibody for severe asthma designed for twice-yearly dosing; currently in phase 3 trials.
• GB-4362 Candidate: Specialized protein designed to neutralize toxic payloads, such as monomethyl auristatin E (MMAE).
• GB-5267 Candidate: Specialized immune cell therapy, known as a CAR-T, developed to target specific cancer proteins.

Strategic Steps Forward

• Entered a collaboration with Novartis in September 2024 to discover and develop multiple protein therapeutics.
• Expanded an existing biologic protein research program with Amgen in December 2023.
• Acquired all outstanding shares of PMCo on Feb. 26, 2026, to consolidate research efforts.
• Closed an initial public offering on March 2, 2026, which resulted in net proceeds of $369.3 million.

Why the Technology Differs

Generate Biomedicines uses a loop of computer design and laboratory testing to create therapeutic solutions. This process helps the company address medical challenges that traditional drug-discovery methods cannot solve.

A Look at the Numbers

• Collaboration revenue was $13.5 million for the six months ended June 30, 2026.
• Research and development expenses reached $122.1 million for the six months ended June 30, 2026.
• Net loss was $129.0 million during the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026.

Bottom Line

Generate Biomedicines has transitioned from a private research entity to a public clinical-stage biotechnology firm. Its shift toward late-stage clinical trials and large pharmaceutical partnerships marks a maturing strategy in the generative biology sector.